Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin

Experimental Dermatology

Volumn 13, Issue 1, 2004, Pages 5-10

  Tang, Liren ^a   Cao, L ^a   Sundberg, J P ^b   Lui, H ^a   Shapiro, J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JACKSON LABORATORY   (United States)

Author keywords

C3H HeJ mice; Cytokine; Topical therapy

Indexed keywords

CYTOKINE; DITHRANOL; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA AREATA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CALCULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HAIR GROWTH; HAIR LOSS; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; OINTMENT; PROTEIN EXPRESSION;

ADMINISTRATION, TOPICAL; ALOPECIA AREATA; ANIMALS; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HAIR; MALE; MICE; MICE, INBRED C3H; OINTMENTS; PSORIASIS; REPRODUCIBILITY OF RESULTS; RNA; SKIN TRANSPLANTATION;

EID: 0842264834     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2004.00098.x     Document Type: Article

References (29)

1. Safavi K H, Muller S A, Suman V J, Moshell A N, Melton L J III. Incidence of alopecia areata in Osmsted Country, Minnesota 1975 through 1989. Mayo Clin Proc 1995: 70: 28-633.
2. Shapiro J. Hair Loss: Principles of Diagnosis and Management. London: Martin Dunitz Ltd, 2002.
3. Randall V A. Is alopecia areata an autoimmune disease? Lancet 2001: 358: 1922-1923.
4. McElwee K J, Tobin D J, Bystryn J C, King L E, Sundberg J P. Alopecia areata: An autoimmune disease? Exp Dermatol 2000: 8: 371-379.
5. Perret C, Weisner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venerol 1984: 64: 26-30.
6. Todes-Taylor N R, Turner B S, Wood B S, Staratte P T, Morhenn V B. T cell subpopulations in alopecia areata. J Am Acad Dermatol 1984: 11: 216-223.
7. Shapiro J, Price V H. Hair regrowth therapeutic agents. Dermatol Clin 1998: 16: 341-356.
8. Fiedler-Weiss V C, Buys C M. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987: 123: 1491-1493.
9. Fiedler V C, Wendrow A, Szpunar G J, Metzler C, DeVillez R L. Treatment-resistant alopecia areata: Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990; 126: 756-759.
10. Schmoeckel C, Weissmann I. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979: 115: 1254-1255.
11. Nelson D A, Spielvogel R L. Anthralin therapy for alopecia areata. Int J Dermatol 1985: 24: 606-607.
12. Sundberg J P, Cordy W R, King L E. Alopecia areata in aging C3H/HeJ mice. J Invest Dermatol 1994: 102: 847-856.
13. Sundberg J P, King L E. Mouse models for the study of human hair loss. Dermatol Clin 1996: 14: 619-632.
14. McElwee K J, Boggess D, King L E, Sundberg J P. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol 1999: 111: 797-803.
15. Freyschmidt-Paul P, Sundberg J P, Happle R et al. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squari acid dibutylester (SADBE) in C3H/HeJ mice. J Invest Dermatol 1999: 113: 61-68.
16. Freyschmidt-Paul P, Hoffman R, Levin E, Sundberg J P, Happle R, McElwee K J. Current and potential therapeutic agents for the treatment of alopecia areata. Curr Pharmaceut Design 2001: 7: 213-230.
17. Freyschmidt-Paul P, Ziegler A, McElwee K J et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus). Eur J Dermatol 2001: 11: 405-409.
18. Shapiro J, Sundberg J P, Bissonnette R et al. Alopecia areata-like hair loss in C3H/HeJ mice and DEBR rats can be reversed using topical diphencyprone. J Invest Dermatol Sym Proc 1999: 4: 239.
19. Tang L, Cao L, Bernado O et al. Topical mechlorethamine restores autoimmune-arrested follicular activity in mice with an alopecia areata-like disease by targeting infiltrated lymphocytes. J Invest Dermatol 2003: 120: 400-406.
20. Tang L, Sundberg J P, Lui H, Shapiro J. Old wine in new bottles: Reviving old therapies for alopecia areata using rodent models. J Invest Dermatol Symp Proc 2003: (in press).
21. Müller K. Anti-psoriatic and proinflammatory action of anthralin: Implications for the role of oxygen radicals. Biochem Pharmacol 1997: 53: 1215-1221.
22. Lange R W, Germolec D R, Foley J F, Luster M I. Antioxidants attenuate anthralin-induced skin inflammation in BALB/c mice: Role of specific proinflammatory cytokines. J Leuk Biol 1998: 64: 170-177.
23. Mrowietz U, Jessat H, Schahrz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol 1997: 136: 542-547.
24. Schmidt K N, Podda M, Packer L, Baeuerle P A. Anti-psoriatic drug anthralin activates transcriptional factor NF-κB in murine keratinocytes. J Immunol 1996: 156: 4514-4519.
25. Hoffmann R, Wenzel E, Huth A et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenlcyclopropenone. J Invest Dermatol 1994: 103: 530-533.
26. Carroll J M, Crompton T, Seery J P, Watt F M. Transgenic mice expressing INF-γ in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol 1997: 108: 412-422.
27. Philpott M P, Sanders D A, Bowen J, Kealey T. Effects of interleukins, colony-stimulating factor and tumor necrosis factor on human hair follicle growth in vitro: A possible role for interleukin-1 and tumor necrosis factor-α in alopecia areata. Br J Dermatol 1996: 135: 942-948.
28. Cope A P. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998: 10: 669-676.
29. Firestein G S. Novel therapeutic strategies involving animals, arthritis, and apoptosis. Curr Opin Rheumatol 1998: 10: 236-241.